Because pancreatic cancer is difficult to detect at early stages, 80% of the patients are diagnosed as impossible for surgical resection. In addition, the 5year survival rate of pancreatic cancer is less than 10%, the lowest among all cancer types. It has a high mortality rate and is known to have a prognosis with an average life span of 17 to 20 months.
The resistance derived from Gemcitabine, which is used as a first treatment, is reduced when combined with other cytotoxic anti-cancer drugs, but these methods still do not overcome the drug resistance.
BeyondBio's anti-cancer drug is expected to inhibit the recurrence and growth of cancer, leading to better treatment. In addition, it is expected to be a good combination with Gemcitabine, increasing the survival rate of cancer patients and improving their quality of life- especially those struggling with metastatic disease.